Uric acid is reduced in the substantia nigra in parkinson's disease: Effect on dopamine oxidation

Brain Research Bulletin

Volumn 33, Issue 4, 1994, Pages 419-425

  Church, W H ^a   Ward, V L ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Catalase; Dopamine oxidation; Iron; Neurodegeneration; Nigro striatal dopamine; Parkinson's disease; Uric acid

Indexed keywords

ASCORBIC ACID; CATALASE; DOPAMINE; URATE OXIDASE; URIC ACID;

ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; HUMAN; HUMAN TISSUE; NIGRONEOSTRIATAL SYSTEM; OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA; TISSUE LEVEL;

AGED; ASCORBIC ACID; BRAIN CHEMISTRY; DOPAMINE; FEMALE; HUMAN; MALE; NERVE DEGENERATION; NEURAL PATHWAYS; OXIDATION-REDUCTION; PARKINSON DISEASE; SUBSTANTIA NIGRA; SUPPORT, NON-U.S. GOV'T; TISSUE EXTRACTS; URIC ACID;

EID: 0028036368     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/0361-9230(94)90285-2     Document Type: Article

References (67)

1. Are dopaminergic neurons selectively vulnerable to Parkinson's disease?
2. Inhibition of nigral dopamine neurons by systemic and local apomorphine: Possible contribution of dendritic autoreceptors
3. Brain peroxidase and catalase in Parkinson disease
4. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: A hypothesis
5. Hydrogen Peroxide Dependent Oxidative Degradation of DNA by Copper Epinephrine
6. The iron chelator desferrioxamine (Desferal) retards 6-Hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons
7. Iron-melanin interaction and lipid peroxidation: Implications for Parkinson's disease
8. Intranigral iron injection induces behavioral and biochemical “Parkinsonism” in rats
9. Role of dendritic dopamine of the substantia nigra in the modulation of nigrocollicular gamma-aminobutyric acid release: In vivo studies in the rat
10. Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced Parkinsonism
11. Inhibition of free radical-induced DNA damage by uric acid
12. Monoamine oxidase, hydrogen peroxide, and Parkinson's disease
13. Urate and ascorbate: Their possible roles as antioxidants in determining longevity of mammalian species
14. Uric acid-iron ion complexes
15. Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia
16. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease
17. Determination of release of endogenous dopamine from superfused substantia nigra slices
18. The endogenous toxin hypothesis of the etiology of Parkinson's disease and a pilot trial of high-dosage antioxidants in an attempt to slow the progression of the illness
19. Manganese catalysis of dopamine oxidation
20. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: A LAMMA study
21. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones
22. Catecholamine toxicity: A proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease
23. Autoxidation vs. covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro
24. Iron and oxygen: A biologically damaging mixture
25. Oxidants and the central nervous system: some fundamental questions. Is oxidant damage relevant to Parkinson's disease, Alzheimer's disease, traumatic injury or stroke?
26. Oxygen free radicals and iron in relation to biology and medicine: Some problems and concepts
27. Iron and free radical reactions: Two aspects of antioxidant protection
28. Measurement of uric acid, ascorbic acid, and related metabolites in biological fluids
29. Uric acid: Functions and determination
30. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: Possible neurochemical mechanisms
31. Enhancement by catechols of hydroxyl-radical formation in the presence of ferric ions and hydrogen peroxide
32. Iron-melanin complex in substantia nigra of parkinsonian brains: An X-ray microanalysis
33. Clues to the mechanism underlying dopamine cell death in Parkinson's disease.
34. Oxidative stress as a cause of Parkinson's disease
35. Lever pressing for food reward and changes in dopamine turnover and uric acid in rat caudate and nucleus accumbens studied chronically by in vivo voltammetry
36. Peroxidatic oxidation of catecholamines. A kinetic electron spin resonance investigation using the spin stabilization approach
37. Stimulatory and inhibitory effects of manganous and ferrous Ions on epinephrine oxidation
38. Uric acid is released in the zona incerta of the subthalamic region of the sheep during rumination and in response to feeding and drinking stimuli
39. Intracranial dialysis measurement of oxytocin, monoamine and uric acid release from the olfactory bulb and substantia nigra of sheep during parturition, suckling, separation from lambs, and eating
40. Glutathione peroxidase activity in Parkinson's disease brain
41. The pharmacology of Parkinson's disease therapy: An update
42. Catecholamine stimulation of copper dependent haemolysis: Protective action of Superoxide dismutase, catalase, hydroxyl radical scavengers and serum proteins (ceruloplasmin, albumin, and apotransfemn)
43. Copper catalyzed oxidation of ascorbate (vitamin C): Inhibitory effect of catalase, Superoxide dismutase, serum proteins (ceruloplasmin, albumin, apotransferrin) and amino acids
44. Transition metals as catalysts of “autoxidation” reactions
45. Voltammetric evidence in vivo of cholinergic modulation of extracellular ascorbic acid and uric acid in rat striatum
46. The effects of haloperidol and amphetamine on ascorbic acid and uric acid in caudate and nucleus accumbens of rats as measured by voltammetry in vivo
47. In vivo voltammetric evidence of production of uric acid by rat caudate
48. Biochemical aspects of Parkinson's disease
49. Inhibition of lipid peroxidation by methylated analogues of uric acid
50. Uric acid levels and dopamine transmission in rat striatum: Diurnal changes and effects of drugs
51. The effect of melanin on iron-associated decomposition of hydrogen peroxide
52. Studies on the autoxidation of dopamine: Interaction with ascorbate
53. The specific vulnerability of the substantia nigra to MPTP is related to the presence of transition metals
54. Similar functions of uric acid and ascorbate in man?
55. Formation of hydroxyl radicals from hydrogen peroxide in the presence of iron
56. On-off effects in Parkinson's disease: A controlled investigation of ascorbic acid therapy
57. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
58. A selective increase in paniculate Superoxide dismutase activity in parkinsonian substantia nigra
59. Iron induces degeneration of nigrostriatal neurons
60. Infusion of iron into the rat substantia nigra: Nigral pathology and dose-dependent loss of striatal dopaminergic markers
61. Conservation of vitamin C by uric acid in blood
62. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease
63. Dopa and dopamine cause cultured neuronal death in the presence of iron
64. Brain iron metabolism: Biochemicals and behavioral aspects in relation to dopaminergic neurotransmission
65. Modulation of dopamine receptor in the striatum by iron: Behavioral and biochemical correlates
66. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?
67. Iron in brain function and dysfunction with emphasis on Parkinson's disease